Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics' stock experienced several notable events over the past six months. In November 2025, the company reported strong third-quarter results and approved a share repurchase program. Despite exceeding preliminary fourth-quarter 2025 revenue expectations, the stock closed down due to a decline in new patient starts for VYKAT XR. Investor investigations and short-seller criticisms also contributed to a decline in shares. Pivotal Phase 3 results for VYKAT XR were published in the Journal of Clinical Endocrinology and Metabolism. Analysts upgraded Soleno Therapeutics from a "hold" rating to a "strong-buy" rating. The stock has experienced significant volatility, with a 52-week range between approximately $41.50 and $90.32.

Information regarding specific demand seasonality for Soleno Therapeutics, Inc.'s products and services was not found in the provided search results. Product demand is typically driven by patient diagnosis and treatment initiation rather than seasonal fluctuations.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases. Their lead product, VYKAT XR, is the first FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome in adults and children four years and older. The FDA approved VYKAT XR on March 26, 2025, transitioning the company to a commercial entity.

Soleno Therapeutics is headquartered in Redwood City, California, United States. The company's stock is listed on the Nasdaq Capital Market in the US, as well as on Deutsche Boerse AG and Borsa Italiana, indicating a presence in European markets.

Soleno Therapeutics' brand reputation has been shaped by the FDA approval and commercial launch of VYKAT XR. The FDA approval positively impacted its reputation, demonstrating its ability to translate scientific innovation into market value. However, a negative report from short-sellers raised criticisms regarding VYKAT XR's safety profile and pricing concerns, leading to investor investigation notices and impacting market sentiment.

Soleno Therapeutics, Inc. has an ownership structure heavily concentrated in institutional hands. As of late 2025, Soleno Therapeutics had 516 institutional owners holding a total of 72,300,087 shares. Andrew Sinclair is the largest individual shareholder, owning 28.34 million shares, representing 52.76% of the company. Insiders collectively own a substantial portion, around 218.88% of the company.